Cargando…

Clinicopathological characteristics, treatment and survival of pulmonary large cell neuroendocrine carcinoma: a SEER population-based study

BACKGROUND: This study was designed to investigate the clinicopathological characteristics, treatment and survival of patients with pulmonary large cell neuroendocrine carcinoma (LCNEC). METHODS: The Surveillance, Epidemiology and End Results database was utilized to identify patients diagnosed with...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Ling, Li, Zhi-wen, Wang, Min, Zhang, Ting-ting, Bao, Bo, Liu, Yun-peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PeerJ Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441320/
https://www.ncbi.nlm.nih.gov/pubmed/30944773
http://dx.doi.org/10.7717/peerj.6539
_version_ 1783407534430748672
author Cao, Ling
Li, Zhi-wen
Wang, Min
Zhang, Ting-ting
Bao, Bo
Liu, Yun-peng
author_facet Cao, Ling
Li, Zhi-wen
Wang, Min
Zhang, Ting-ting
Bao, Bo
Liu, Yun-peng
author_sort Cao, Ling
collection PubMed
description BACKGROUND: This study was designed to investigate the clinicopathological characteristics, treatment and survival of patients with pulmonary large cell neuroendocrine carcinoma (LCNEC). METHODS: The Surveillance, Epidemiology and End Results database was utilized to identify patients diagnosed with pulmonary LCNEC between 2004 and 2013. Kaplan–Meier analysis was conducted to determine the overall survival (OS) and cancer-specific survival (CSS) rate. Univariate survival analysis along with log-rank test, and Cox proportional hazards model were employed to detect independent prognostic factors. RESULTS: Pulmonary LCNEC accounted for 0.58% (2972/510607) of the total number of lung and bronchus carcinoma. And a total of 1,530 eligible cases were identified, with the median follow-up time of 11 months. To be specific, the 3-, 5-year OS and CSS rates were 22.8%, 16.8% and 26.5%, 20.8% respectively. Generally, pulmonary LCNEC was commonly detected in the elderly (72.2%), males (55.9%), the upper lobe (62.0%) and advanced AJCC stage (65.5%). Multivariate analysis revealed that elderly [(≥60 and <80 years) HR:1.203, 95% CI [1.053–1.375], P = 0.007; (≥80 years) HR:1.530, 95% CI [1.238–1.891], P < 0.001] and advanced AJCC stage [(stage III) HR:2.606, 95% CI [2.083–3.260], P < 0.001; (stage IV) HR:4.881, 95% CI [3.923–6.072], P < 0.001] were independent unfavorable prognostic factors, and that female (HR:0.845, 95% CI [0.754–0.947], P = 0.004)), surgery [(Segmentectomy/wedge resection) HR:0.526, 95% CI [0.413–0.669], P < 0.001; (Lobectomy/Bilobectomy) HR:0.357, 95% CI [0.290–0.440], P < 0.001;(Pneumonectomy) HR:0.491, 95% CI [0.355–0.679], P < 0.001] , chemotherapy (HR:0.442, 95% CI [0.389–0.503], P < 0.001) and radiation (HR:0.837, 95% CI [0.738–0.949], P = 0.005) were independent favorable prognostic factors. CONCLUSION: To sum up, age at diagnosis, sex, AJCC 8th edition stage, surgery, chemotherapy and radiation were significantly associated with OS of patients with pulmonary LCNEC.
format Online
Article
Text
id pubmed-6441320
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher PeerJ Inc.
record_format MEDLINE/PubMed
spelling pubmed-64413202019-04-03 Clinicopathological characteristics, treatment and survival of pulmonary large cell neuroendocrine carcinoma: a SEER population-based study Cao, Ling Li, Zhi-wen Wang, Min Zhang, Ting-ting Bao, Bo Liu, Yun-peng PeerJ Epidemiology BACKGROUND: This study was designed to investigate the clinicopathological characteristics, treatment and survival of patients with pulmonary large cell neuroendocrine carcinoma (LCNEC). METHODS: The Surveillance, Epidemiology and End Results database was utilized to identify patients diagnosed with pulmonary LCNEC between 2004 and 2013. Kaplan–Meier analysis was conducted to determine the overall survival (OS) and cancer-specific survival (CSS) rate. Univariate survival analysis along with log-rank test, and Cox proportional hazards model were employed to detect independent prognostic factors. RESULTS: Pulmonary LCNEC accounted for 0.58% (2972/510607) of the total number of lung and bronchus carcinoma. And a total of 1,530 eligible cases were identified, with the median follow-up time of 11 months. To be specific, the 3-, 5-year OS and CSS rates were 22.8%, 16.8% and 26.5%, 20.8% respectively. Generally, pulmonary LCNEC was commonly detected in the elderly (72.2%), males (55.9%), the upper lobe (62.0%) and advanced AJCC stage (65.5%). Multivariate analysis revealed that elderly [(≥60 and <80 years) HR:1.203, 95% CI [1.053–1.375], P = 0.007; (≥80 years) HR:1.530, 95% CI [1.238–1.891], P < 0.001] and advanced AJCC stage [(stage III) HR:2.606, 95% CI [2.083–3.260], P < 0.001; (stage IV) HR:4.881, 95% CI [3.923–6.072], P < 0.001] were independent unfavorable prognostic factors, and that female (HR:0.845, 95% CI [0.754–0.947], P = 0.004)), surgery [(Segmentectomy/wedge resection) HR:0.526, 95% CI [0.413–0.669], P < 0.001; (Lobectomy/Bilobectomy) HR:0.357, 95% CI [0.290–0.440], P < 0.001;(Pneumonectomy) HR:0.491, 95% CI [0.355–0.679], P < 0.001] , chemotherapy (HR:0.442, 95% CI [0.389–0.503], P < 0.001) and radiation (HR:0.837, 95% CI [0.738–0.949], P = 0.005) were independent favorable prognostic factors. CONCLUSION: To sum up, age at diagnosis, sex, AJCC 8th edition stage, surgery, chemotherapy and radiation were significantly associated with OS of patients with pulmonary LCNEC. PeerJ Inc. 2019-03-27 /pmc/articles/PMC6441320/ /pubmed/30944773 http://dx.doi.org/10.7717/peerj.6539 Text en © 2019 Cao et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited.
spellingShingle Epidemiology
Cao, Ling
Li, Zhi-wen
Wang, Min
Zhang, Ting-ting
Bao, Bo
Liu, Yun-peng
Clinicopathological characteristics, treatment and survival of pulmonary large cell neuroendocrine carcinoma: a SEER population-based study
title Clinicopathological characteristics, treatment and survival of pulmonary large cell neuroendocrine carcinoma: a SEER population-based study
title_full Clinicopathological characteristics, treatment and survival of pulmonary large cell neuroendocrine carcinoma: a SEER population-based study
title_fullStr Clinicopathological characteristics, treatment and survival of pulmonary large cell neuroendocrine carcinoma: a SEER population-based study
title_full_unstemmed Clinicopathological characteristics, treatment and survival of pulmonary large cell neuroendocrine carcinoma: a SEER population-based study
title_short Clinicopathological characteristics, treatment and survival of pulmonary large cell neuroendocrine carcinoma: a SEER population-based study
title_sort clinicopathological characteristics, treatment and survival of pulmonary large cell neuroendocrine carcinoma: a seer population-based study
topic Epidemiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441320/
https://www.ncbi.nlm.nih.gov/pubmed/30944773
http://dx.doi.org/10.7717/peerj.6539
work_keys_str_mv AT caoling clinicopathologicalcharacteristicstreatmentandsurvivalofpulmonarylargecellneuroendocrinecarcinomaaseerpopulationbasedstudy
AT lizhiwen clinicopathologicalcharacteristicstreatmentandsurvivalofpulmonarylargecellneuroendocrinecarcinomaaseerpopulationbasedstudy
AT wangmin clinicopathologicalcharacteristicstreatmentandsurvivalofpulmonarylargecellneuroendocrinecarcinomaaseerpopulationbasedstudy
AT zhangtingting clinicopathologicalcharacteristicstreatmentandsurvivalofpulmonarylargecellneuroendocrinecarcinomaaseerpopulationbasedstudy
AT baobo clinicopathologicalcharacteristicstreatmentandsurvivalofpulmonarylargecellneuroendocrinecarcinomaaseerpopulationbasedstudy
AT liuyunpeng clinicopathologicalcharacteristicstreatmentandsurvivalofpulmonarylargecellneuroendocrinecarcinomaaseerpopulationbasedstudy